Clinical trial
IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative…
NCT00228852 · Emory University, Other · Completed
Key facts
| NCT number | NCT00228852 |
|---|---|
| Title | IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency |
| Official title | Phase I/II Trial of De-Escalation of Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency |
| Lead sponsor | Emory University, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | T-Cell Immune Deficiency Diseases, Severe Combined Immunodeficiency |
| Intervention type | Drug |
| Interventions | Busulfan, Fludarabine and ATG |
| Completion | Nov 1, 2006 |
| First posted | Sep 29, 2005 |
| Last update posted | Jun 30, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: